Shaomeng Wang

发表

Hepatic TRAF2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses

L. Rui, R. Brink, Yujun Zhao, 2012, Diabetes.

Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice

A. Lok, L. Rui, S. Liangpunsakul, 2022, Nature Communications.

Proerectile Effects of Dopamine D2-Like Agonists Are Mediated by the D3 Receptor in Rats and Mice

D. Grandy, Shaomeng Wang, R. Sunahara, 2009, Journal of Pharmacology and Experimental Therapeutics.

Therapeutic Strategies to Target the Androgen Receptor.

Weiguo Xiang, Shaomeng Wang, 2022, Journal of medicinal chemistry.

Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction.

Lina Ding, Linlin Yang, Xiao-Jing Shi, 2019, Journal of medicinal chemistry.

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.

J. Rae, Shaomeng Wang, R. Rej, 2023, Journal of medicinal chemistry.

A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

Wei Jiang, J. Stuckey, D. McEachern, 2023, Nature Chemical Biology.

Targeting MDM2 for the development of a new cancer therapy: progress and challenges

A. Aguilar, Shaomeng Wang, J. E. Thomas, 2023, Medicinal Chemistry Research.

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity.

Wei Jiang, B. Miao, Duxin Sun, 2023, Journal of medicinal chemistry.

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

D. McEachern, B. Miao, Mi Wang, 2023, Journal of medicinal chemistry.

Discovery of Pyrrolo[2,3-c]pyridines as Potent and Reversible LSD1 Inhibitors.

Mi Wang, Shaomeng Wang, Chao-Yie Yang, 2023, ACS medicinal chemistry letters.